Cadrenal Therapeutics(CVKD) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq
BusinesswireApr 17 09:40 ET
Express News | Cadrenal Therapeutics Inc - Files Prospectus Supplement for $2.17 Mln Atm Offering - SEC Filing
ReutersApr 17 06:12 ET
Is Cadrenal Therapeutics (NASDAQ:CVKD) In A Good Position To Deliver On Growth Plans?
Yahoo FinanceApr 6 09:16 ET
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
BusinesswireApr 3 08:00 ET
Cadrenal Therapeutics | 10-K: FY2024 Annual Report
SECMar 13 17:16 ET · Announcements
Express News | Cadrenal Therapeutics FY 2024 GAAP EPS $(8.73) Misses $(7.59) Estimate
BenzingaMar 13 16:21 ET

Comments

Teddy123

Mar 14 13:49

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

$Cadrenal Therapeutics (CVKD.US)$ $Abbott Laboratories (ABT.US)$
Cadrenal Secures FDA Orphan Drug Status and Abbott Partnership for Breakthrough Phase 3 Trial

Jaguar8

Mar 4 21:08

NEWS

$Cadrenal Therapeutics (CVKD.US)$
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
Tuesday, 4th March at 8:00 am
Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), a late-stage biopharmaceutical company focused on the development of spec...

1

Trytosaveabit

Mar 4 21:07

news

$Cadrenal Therapeutics (CVKD.US)$ Reuters
4 mins ago
Cadrenal Therapeutics Announces Collaboration Agreement With Abbott in Support of Pivotal Study of Tecarfarin in Patients With Heartmate 3™ Lvad